Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
BACKGROUND: The aim of this study was to evaluate the clinical impact of a combination of systemic sequential therapy and locoregional therapy on the long-term survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC).
METHODS: Sixty-four consecutive patients with intrahepatic target nodules who had initially received systemic therapy (lenvatinib and atezolizumab plus bevacizumab) were reviewed. The clinical impact of the combined use of systemic sequential therapy and locoregional therapy was evaluated by determining overall survival (OS). The combined use of systemic sequential therapy with more than two agents and locoregional treatment was defined as multidisciplinary combination therapy (MCT), while only systemic sequential therapy and repeated locoregional-treatment was defined as a single treatment procedure (STP).
RESULTS: R0 resection, MCT, and STP resulted in significantly better OS compared with no additional treatment (median OS, not reached vs. 18.2 months and 12.6 vs. 8.1 months, respectively; p = 0.002). Multivariate analysis confirmed that the use of R0 resection and MCT were associated with better OS (hazard ratio [HR]; 0.053, p = 0.006 and 0.189, p < 0.001, respectively) compared with that for STP (HR; 0.279, p = 0.003).
CONCLUSIONS: MCT is may effective in patients with BCLC stage C HCC and intrahepatic target nodules who have previously received systemic therapy-based treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 15 vom: 26. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kawamura, Yusuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atezolizumab plus bevacizumab |
|---|
| Anmerkungen: |
Date Revised 14.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15153789 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360681115 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360681115 | ||
| 003 | DE-627 | ||
| 005 | 20231226083529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15153789 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360681115 | ||
| 035 | |a (NLM)37568605 | ||
| 035 | |a (PII)3789 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kawamura, Yusuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: The aim of this study was to evaluate the clinical impact of a combination of systemic sequential therapy and locoregional therapy on the long-term survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) | ||
| 520 | |a METHODS: Sixty-four consecutive patients with intrahepatic target nodules who had initially received systemic therapy (lenvatinib and atezolizumab plus bevacizumab) were reviewed. The clinical impact of the combined use of systemic sequential therapy and locoregional therapy was evaluated by determining overall survival (OS). The combined use of systemic sequential therapy with more than two agents and locoregional treatment was defined as multidisciplinary combination therapy (MCT), while only systemic sequential therapy and repeated locoregional-treatment was defined as a single treatment procedure (STP) | ||
| 520 | |a RESULTS: R0 resection, MCT, and STP resulted in significantly better OS compared with no additional treatment (median OS, not reached vs. 18.2 months and 12.6 vs. 8.1 months, respectively; p = 0.002). Multivariate analysis confirmed that the use of R0 resection and MCT were associated with better OS (hazard ratio [HR]; 0.053, p = 0.006 and 0.189, p < 0.001, respectively) compared with that for STP (HR; 0.279, p = 0.003) | ||
| 520 | |a CONCLUSIONS: MCT is may effective in patients with BCLC stage C HCC and intrahepatic target nodules who have previously received systemic therapy-based treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a atezolizumab plus bevacizumab | |
| 650 | 4 | |a combination therapy | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a lenvatinib | |
| 650 | 4 | |a locoregional treatment | |
| 650 | 4 | |a systemic therapy | |
| 700 | 1 | |a Akuta, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Shindoh, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumura, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Okubo, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tominaga, Licht |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiyama, Shunichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hosaka, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Saitoh, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sezaki, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Fumitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Yoshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Arase, Yasuji |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Masaji |e verfasserin |4 aut | |
| 700 | 1 | |a Kozuka, Takuyo |e verfasserin |4 aut | |
| 700 | 1 | |a Kumada, Hiromitsu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 15 vom: 26. Juli |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:15 |g day:26 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15153789 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 15 |b 26 |c 07 | ||